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a b s t r a c t
Ethnopharmacological relevance: Berberine (BER) and BER-original herbal medicines have a variety of
pharmacological functions and have been widely used in clinical. However, its effect of enzyme induction
on cytochrome P450 (CYP) in human hepatocytes is unknown.
Material and method: Metabolism of berberine and its effect on main metabolic enzymes in HepG2 cell
in vitro was investigated. Cocktail probe drugs, mRNA expression and protein expression were used to
evaluate the metabolism potency. Meanwhile, an UPLC–MS/MS method was validated for the analysis of
BER and four probe drugs in HepG2 cell.
Result: BER signiﬁcantly increased the metabolism of midazolam, phenacetin and tolbutamide by
inducing the CYP1A2 and 3A4 enzyme in a dose-dependent manner, the mRNA and protein expression
of CYP1A2 and 3A4 were increased by berberine at 1000 ng mL1. The activity of CYP1A2 and 3A4 could
be induced by BER more than 500 ng mL1 in HepG2 cell, which was conﬁrmed by the increase of its
mRNA and protein expression.
Conclusion: BER increases the metabolism of cocktail drugs such as midazolam, phenacetin and
tolbutamide by increasing the mRNA and protein expression of CYP1A2 and 3A4.
& 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
1. Introduction
During the research of adverse reactions from Chinese herbal
medicine (Derosa et al., 2012; Lu et al., 2012; Richard, 2004), the
drug–drug interaction between Chinese herbal medicines and
Western chemical-based drugs causes problems due to adverse
effects from genetic polymorphisms of metabolic enzyme (Chan
et al., 2010; Iwata et al., 2004; Thomas et al., 2005; Wu et al., 2012;
Yoshida et al., 2013). Berberine (BER; also known as berberine
hydrochloride) is an isoquinoline alkaloid (Fig. 1) from Coptis
chinensis Franch in China and Hydrastis canadensis in north
American (Grycová et al., 2007; Gurley et al., 2005, 2007; Wang
et al., 2004). Studies show that BER have multiple pharmacological
activities, such as regulation of glucose and lipid, anti-bacterial,
anti-inﬂammatory, anti-diarrheal, anti-tumor, anti-arrhythmia,
immunosuppression and anti-cancer (Arayne et al., 2007; Choi
et al., 2007; Cicero and Ertek, 2009; Derosa et al., 2006; Enk et al.,
2007; Efferth et al., 2005; Gulfraz et al., 2008; Kim et al., 2008;
Seraﬁm et al., 2008; Tang et al., 2009; Ye et al., 2009). The
combination of BER and its original medicine may cause drug–
drug interactions (DDI) through induce or inhibit the metabolic
enzyme and transporters in the present of disposition procedures
of medicine (Islam et al., 2008; Pan et al., 2002; Turner et al.,
2008; Zuo et al., 2006), such as metabolic enzymes proﬁle
(Chatuphonprasert et al., 2012; Guo et al., 2011a, 2011b; Gurley
et al., 2005; Hermann and Richter, 2012; Vrzal et al., 2005) and its
gene transcription (Qin et al., 2006; Wang et al., 2011; Xia et al.,
2007), efﬂux transporters (Borges-Walmsley et al., 2003; Fahrmayr
et al., 2012; Sorensen and Dearing, 2006; Zha et al., 2013), and the
metabolites (Guo et al., 2011a, 2011b; Li et al., 2011; Liu et al.,
2010). The metabolism of BER is mainly mediated by CYP1A2, 3A4,
2D6 enzymes and UDP-glucuronosyltransferases, which was meta-
bolized with phase I demethylation and phase II glucuronidation
in liver. Its metabolites are berberrubine, demethyleneberberine,
jatrorrhizine, thalifendine and its glucuronidation compounds
(Guo et al., 2011a, 2011b; Han et al., 2011; Li et al., 2011; Liu
et al., 2009, 2010; Zuo et al., 2006). Meanwhile, BER could inhibit
or induce the activity of CYP enzyme (Chen et al., 2013a, 2013b;
Zuo et al., 2006), which is a result of the increase or decrease of the
bioavailability of drug such as verapamil, losartan, probenecid,
cyclosporine A, cloxacillin, digoxin, pravastatin, midazolam and
quinidine (Bhadra and Kumar, 2011; Chatterjee and Franklin,
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2003; Chen et al., 2013a, 2013b; Guo et al., 2012; Gurley et al.,
2007; Kong et al., 2008; Liu et al., 2009; Musumeci et al., 2003;
Pan et al., 2002; Quan et al., 2006; Shi et al., 2009; Tong et al.,
2012; Tsai and Tsai, 2004; Tsai and Tsai, 2005; Wang et al., 2013;
Wu et al., 2005; Xin et al., 2006; Zhang et al., 2011; Zhao et al.,
2012; Zuo et al., 2006, 2011). However, the induction effect of BER
on hepatic CYP enzymes and the potency evaluation of the DDI are
not clear.
In this study, we investigated the BER on intrinsic hepatic clearance
in vitro using HepG2 cell. The HepG2 cell activity was determined by
the 3-(4, 5-dimethylthiazole-2-yl)-2, 5-diphenyltetraz-oliumbromide
(MTT) method. The metabolic potency of BER on the CYP enzyme was
assessed using a cocktail approach via probe drugs phenacetin
(1A2), midazolam (3A4), tolbutamide (2C9) and chlorzoxazone (2E1)
approved by FDA database (Drug Development and Drug Interactions,
2011; Chu et al., 2009). The probe drug and BER was determined by an
UPLC–MS/MS system. The mRNA and protein expression of CYP1A2
and 3A4 were analyzed by western blotting and reverse transcription–
polymerase chain reaction (RT–PCR). Result showed that BER could
induce the activity of CYP1A2 and 3A4 in HepG2 cells, which is
consistent with the increase of the enzyme gene transcription and
protein expression.
2. Material and method
2.1. Materials and reagents
BER was purchased from National Institutes for Food and Drug
Control (Beijing, China), phenacetin, tolbutamide, chlorzoxazone and
midazolam, non-essential amino acids, western blotting test and
related reagents were purchased from Sigma-Aldrich (St. Louis,
MO, USA). Rifampicin and omeprazole were obtained from Aladdin
(Shanghai, China) RNA extraction kit (K0604), oligo-(dT) (R0815),
ribonuclease inhibitor (R0508), M-MLV reverse transcriptase (R0807),
and BioEasy SYBR Green I Real Time PCR Kit (K0324) were obtained
from Takara Co. LTD (Dalian, China). CYP1A2 antibody was purchased
from CST Inc. (Boston, MA, USA). CYP3A4 antibody was purchased
from Santa Cruz Inc. (Dallas, Texas, USA). Goat anti-rabbit IgG
secondary antibodies were purchased from Jacson Immuno Research
Laboratories Inc. (Pennsylvania, USA). Acetonitrile, methanol, ammo-
nium acetate, and formic acid were HPLC grade, other reagents were
analytical grade. Ultra-pure water was prepared by a Milli-Q.
HepG2 cells were purchased from Cell Culture Center of
Chinese Academy of Medical Sciences (Beijing, China). DMEM
low glucose medium (Gibco, USA) and fetal bovine serum were
obtained from Gibco (Grand Island, New York, USA).
2.2. Preparation of BER, probe drugs and inducer solutions
The standard solution of BER was prepared in methanol at the
concentration of 100 μg mL1. The stock solution was diluted
with cell culture medium to the required concentrations
before use.
Probe drugs and CYP inducers were selected according to FDA
guidance for drug metabolism and drug interaction (Guidance for
Industry, 1997; 2012; Drug Development and Drug Interactions, 2011).
The primary stock solution of probe drugs such as phenacetin
(CYP1A2), tolbutamide (CYP2C9), chlorzoxazone (CYP2E1) and mid-
azolam (CYP3A4) was prepared by dissolving an appropriate amount
in methanol, which was diluted with culture medium before use.
Omeprazole (inducer of CYP1A2) and rifampicin (inducer of CYP3A4)
were dissolved in DMSO–methanol (1:10, v/v), then diluted with
serum-free cell culture medium at the concentration of 10 and
40 μmol  L1 (DMSO and methanol less than 0.1% and 1%),
respectively.
2.3. Apparatus
A synergy 2 microplate reader (Bio Tek. Inc., USA) was used to
measure the absorption. The mRNA expression was detected by the
line-gene real-time ﬂuorescence quantitative PCR system (Bori Science
and Technology Co. Ltd. Hangzhou, China). Western blotting was
performed on MV-3 electrophoresis apparatus, ST-2 transmembrane
meter (J-max Bio-tech Ltd. Dalian, China), and BINTA 2020D gel
imaging analysis system (Binta Instrument Technology Co. Ltd. Beijing,
China). UPLC–MS/MS analysis was carried out on Waters Xevo Triple
Quadrupole mass spectrometer equipped with an electrospray ioniza-
tion source (ESI) and UPLC system (Waters, Milford, MA, USA). The
Masslynx V4.1 ChemStation and Empower 3 workstation were used
for data acquisition. The analytes were separated on an Acquity BEH
C18 column (2.150mm, i.d¼1.7 μm).
2.4. Preparation of HepG2 cell culture
HepG2 cells in the logarithmic growth phase were collected
and adjusted at concentration of 2105/mL or 1106/mL for the
cell suspension during the whole of the experiment, HepG2 cells
were cultured in DMEM low glucose medium containing 10% fetal
bovine serum, 100 U mL1 penicillin and 100 U mL1 strepto-
mycin at 37 1C, with 5% CO2, and 95% relative humidity (Vrzal et
al., 2005., Seeland et al., 2013).
2.5. Preparation of MTT assay for activity of BER on HepG2 cell
This section was conducted according to the literature (Lahoz
et al., 2013; Vrzal et al., 2005; 26). After HepG2 cell suspension in
100 μL (2105/mL) was placed into a 96-well plate with 200 μL of
culture medium and incubated for 24 h, the culture medium was
discarded, BER in 200 μL at different concentrations was added into
each well. Culture medium without HepG2 cell and BER-free culture
medium with HepG2 cell were used as blank and negative groups,
respectively. The cells were incubated at 37 1C with 5% CO2 for 48 h. At
4 h prior to the termination, 20 μL of MTT (5mg mL1 diluted with
PBS buffer) were added into each well, and then 150 μL of DMSO was
added into each well for the termination. The absorbance (A) of each
well was determined via a Synergy 2 microplate reader at wavelength
of 570 nm, survival rate was used to evaluate the effect of BER on
HepG2 cell calculated as formula:
Survival rate ð%Þ ¼ ðAexperiment groupAblankÞ=ðAnegative groupAblankÞ:
2.6. BER on metabolic CYP enzyme procedure
According to the reported method (Gebhardt et al., 2003; Lahoz
et al., 2013), 200 μL of HepG2 cells suspension (2105/mL) was
placed into a 48-well plate with 300 μL of culture medium, mixed
evenly, and incubation for 48 h, when the cell fusion was approxi-
mately 90%, disposal of the medium, 300 μL of BER solution (20,
50, 200, 500 and 1000 ng mL1) was added, respectively, 400 μL
CH3O
N+
OCH3
CH2O
O
Fig. 1. The chemical structure of berberine.
H.-M. Cui et al. / Journal of Ethnopharmacology 158 (2014) 388–396 389
rifampicin (10 μmol  L1) or omeprazole (40 μmol  L1) was
added into each well in two groups incubation for 3 days, then
the medium was discarded, each well was rinsed three times with
drug-free culture medium prior to removal of medium, 500 μL
culture medium with Cocktail probe drugs (58.75 ng mL1 for
midazolam, 95.21 ng mL1 for phenacetin, 266.99 ng mL1 for
tolbutamide and 678.73 ng mL1 for chlorzoxazone) were added
into each well, then the cell was incubated under 37 1C for 4 h.
100 μL sample was collected for procedure with 100 μL of cold
acetonitrile (containing 100 ng mL1 diphenhydramine as inter-
nal standard, 4 1C). The mixture was vortexed for 2 min and then
centrifuged at 13,500g for 15 min. The supernatant was trans-
ferred into a glass vial for UPLC–MS/MS analysis.
2.7. Evaluation the metabolic enzyme of HepG2 cells induced by BER
2.7.1. Induce activity of BER HepG2 cells
To investigate the induce effect of BER on HepG2 cell, 200 μL of
HepG2 cells suspension (1106/mL) was placed into a 6-well plate
and incubation with 2 mL culture medium for 4 days (culture
medium was replaced each 2 days). When cell fusion was approxi-
mately 90%, the medium was discarded; 2 mL of drug-free culture
medium was randomly added into 3 wells as well as the control
group. 2 mL of BER (1.0 μg mL1) was added into the other 3 wells
as well as the BER induced group. After incubation for 3 days, the
mRNA and protein expression of CYP1A2 and 3A4 in each group
were analyzed using RT–PCR and western blotting, respectively.
2.7.2. RT-PCR assessment of CYP1A2 and 3A4 mRNA expression
To evaluate the mRNA expression of CYP1A2 and CYP3A4, the
line-gene real-time ﬂuorescence quantitative PCR was used for
CYP1A2 and 3A4 mRNA expression (Eloranta et al., 2005; Gebhardt
et al., 2003; Lahoz et al., 2013; Luo et al., 2002). The 6-well plate
was washed with culture medium prior to the pre-cooled PBS.
After the removal of PBS, 1 mL of cell lysis solution was added into
each well. The RNA was extracted with a Takara RNA extraction
kit according to the instruction, and its integrity analysis was a
MV-3 electrophoresis apparatus. Based on the CYP1A2 and 3A4
sequences from the NCBI website, the primers were designed
using Primer 6.0 and Oligo 6 software. For human actin with a
product size of 256 bp, the primers were 50-TGACGTGGACATCCG-
CAAAG-3 (forward) and 50-CTGGAAGG-TGGACAGCGAGG-30 (reverse).
For human CYP1A2 with a product size of 165 bp, the primers
were 50-AGCTTCTCCTGGCCTCTGC-30 (forward) and 50-GGACTTTT-
CAGGCCTTTGGG-30 (reverse). For human CYP3A4 with a product
size of 186 bp, the primers were 50-CAGGAGGAAATTGATGCAGTTTT-
30 (forward) and 50-GTCAAGATACTCCATCTGT-AGCACAGT30 (reverse).
The RNA template and primers were mixed in micro-tubes, and the
cDNA solution was obtained using reverse transcription. The real-
time PCR reaction program was performed at 95 1C for 120 s, 95 1C
for 20 s, 58 1C for 25 s, 72 1C for 30 s, 65 1C–95 1C for 20 s with
1.5 1C  s1, for a total of 45 cycles in a procedure. The real-time
ﬂuorescence signal of the ampliﬁed products and melting curve was
analyzed using the number of CYP1A2 and 3A4 mRNA enzyme copies.
2.7.3. Western blotting assessment level of CYP1A2 and 3A4 enzyme
Western blotting test was used to determine the amount of
CYP1A2 and 3A4 (Eloranta et al., 2005; Gebhardt et al., 2003; Lahoz
et al., 2013; Luo et al., 2002). The 6-well plate was washed with culture
medium prior to pre-cool PBS, after that, 2 mL PBS was added to each
well. The cells were collected in the PBS solution. The supernatant was
removed by centrifuge, 200 μL of lysis buffer was added to the
precipitate. The mixture was vortexed and dissociated in an ice bath
for 15 min, then centrifuge at 13500g for 10 min under 4 1C. The
supernatant was transferred into a tube and kept under 20 1C for
next steps. The protein assay was performed at 570 nm along with
standard curve according to the instruction of BCA Protein Assay Kit.
Electrophoresis was carried out with an injection volume equivalent to
20 μg of proteins. The concentrated voltage and separating gel voltage
were 80 V and 120 V, respectively, the gel electrophoresis was
terminated according to the markers (bromophenol blue). The pro-
teins on the gel were transferred onto a polyvinylidene ﬂuoride ﬁber
(PVDF) membrane. After it was rinsed in Tris-buffered saline (TBST) for
5 min, the PVDF membrane was immersed in blocking buffer at room
temperature for 4 h. The incubation with primary antibody (1:1000)
was carried out at 4 1C for 12 h. After it was rinsed with TBST 3 times
for 5 min each, the PVDF membrane was incubated for 4 h with
secondary antibodies labeled by horseradish peroxidase (HRP)
(1:5000), and then it was rinsed again with TBST 3 times for 5 min
each, the membrane was colorized with electrochemiluminescence
(ECL) reagent. The membrane was scanned for gray analysis using Lab
Works image analysis software.
2.8. UPLC-method validation and application
2.8.1. UPLC–MS/MS method validation
The UPLC separation was achieved on an Acquity BEH C18
column at the ﬂow rate of 0.3 mL min1, the column temperature
was 30 1C and the injection volume was 5 μL. For the probe drugs,
the consistent of mobile phase was acetonitrile-0.2% formic acid
(28:72, v/v). For BER, the mobile phase was acetonitrile-
2 mmol  L1 formic acid with addition to 0.05% ammonium
acetate at pH 3.2 (28:72, v/v). For the ESI–MS/MS, the parameter
was optimized by using multiple reaction monitoring (MRM) with
the positive mode for midazolam and phenacetin, and negative
mode for tolbutamide and chlorzoxazone. The ESI source tem-
perature for nebulizing gas was at 500 1C with a ﬂow rate of
850 L h1. For the determination of probe drugs, the parameters
of m/z, cone voltage and collision voltage were 326.01-290.92,
42 V and 24 V for midazolam, 180.06-109.99, 32 V and 16 V for
phenacetin, 269.07-169.96, 30 V and 20 V for tolbutamide, and
167.90-131.92, 36 V and 18 V for chlorzoxazone, respectively. The
MS condition for BER was as follow: m/z 336.23-277.98, cone
voltage and collision voltage were 32 V and 40 V, respectively.
Sample procedure was optimized and obtained as follows:
100 μL of the sample was added with 100 μL cool acetonitrile
(containing 100 ng mL1 diphenhydramine as internal standard,
4 1C), vortexed for 2 min, and then centrifugal at 13500 g for 15 min,
the supernatant was transferred into a glass vial for analysis.
Method for UPLC–MS/MS was validated via the speciﬁcity,
linearity, precision, stability, recovery, lower limit of detection and
quantiﬁcation (LOD and LOQ). For speciﬁcity, the cells cultured in
medium with drugs-free (blank) and with drugs or BER (control)
and samples were collected for UPLC–MS/MS analysis. The chro-
matography obtained for each group is shown in Figs. 2 and 3. For
linearity, the Cocktail probe drug stock solution was diluted at 10,
50, 100, 200, 400, 800 and 1000 ng mL1 with culture medium
and prepared according to sample procedure. Linear regression was
performed with the peak area of each probe drug as y-axis (y) and
the concentration as x-axis (X) weighted by 1/x using internal
standard. Precision test was performed in three levels (20, 200
and 1000 ng mL1) for Cocktail probe drug and BER in six
replicates, which was calculated by peak area with relative standard
deviation (RSD%). For stability, test solution was analyzed at 0, 1, 2,
4, 8 and 24 h after sample preparation and the RSD was calculated.
For recovery, samples were prepared at concentrations of 30.53,
147.60, 150.00, 147.15 and 151.35 ng mL1 for BER, phenacetin,
midazolam, chlorzoxazone and tolbutamide, respectively (n¼6).
The LOD and LOQ were analyzed using BER standard solution,
which was calculated based on signal to noise (S/N), S/NZ3 for LOD
and S/NZ10 for LOQ.
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2.8.2. Metabolism of BER in HepG2 cells procedure for UPLC–MS/MS
analysis
100 μL HepG2 cell suspension (2105/mL) was placed into a
96-well with addition to 200 μL of culture medium, after cells
incubation for 48 h to observe the cell fusion approximately 90%,
the culture medium was discarded. For experimental group, 200 μL
BER at different concentrations (1, 3, 10, 50 and 100 ng mL1) was
added into each well; for control group, BER-free medium was
added into each well (n¼6). After the cell incubation for 4 h under
37 1C, 100 μL of the each solution was collected and prepared for
UPLC–MS/MS analysis.
2.9. Statistical analysis
Data analysis was performed using SPSS 11.5 software. An
independent-samples t test was used for intergroup comparison.
Fig. 2. UPLC–MS/MS chromatograms of 4 probe drugs in vitro HepG2 cells. A. blank sample, B. diphenhydramine, C. midazolam, D. phenacetin, E. Tolbutamide,
F. Chlorzoxazone.
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All data was in the present of mean7standard deviation (SD). For
all analysis, a probability value po0.05 or po0.01 was considered
to be signiﬁcant in statistic.
3. Results
3.1. Effects of BER on HepG2 cell activity
The MTT assay was used to evaluate the HepG2 cell survival
rate served with BER (Table 1). Results showed that there was no
inﬂuence on survival rate of HepG2 cell with the BER concentra-
tion not more than 1000 ng mL1.
3.2. The HepG2 cell intrinsic clearance rate and metabolic dynamics
of BER
According to Michaelis–Menten equation of V¼Vmax S/
(KmþS), the BER metabolic rate was plotted with V (as the y-axis
BER concentration) versus S (as the x-axis), Vmax and Km were
calculated using “Solver Options” by Microsoft Excel software
(Hutzler et al., 2002). Result revealed that Vmax and Km for BER
were 0.14 ng/105 (cell) h1 and 2.82 ng mL1, respectively. The
intrinsic clearance of HepG2 was a ratio of Vmax and Km for BER
(CLin), which was 0.051 mL/105 (cell) h1.
3.3. Effect of BER on CYP enzyme metabolic activity
The metabolism activity of probe drug was assessed by the
relative metabolic rate (Table 3), which was a ratio between
experimental group and control group, the control group was
considered to be 100%. The metabolic activity for probe drug is
shown in Fig. 4, metabolism enzyme of phenacetin, midazolam,
tolbutamide and chlorzoxazone were CYP1A2, 3A4, 2C9 and 2E1,
respectively. Rifampicin is an inducer of CYP3A4 and CYP2C, while
omeprazole is an inducer of CYP1A2, the metabolism rate of
midazolam and tolbutamide were signiﬁcantly (po0.01)
increased by rifampicin induced group (compared with the con-
trol). Meanwhile, metabolism rate of phenacetin was also signiﬁ-
cantly (po0.01) increased by omeprazole induced group
(compared with control). The metabolism rate of midazolam,
phenacetin and tolbutamide was signiﬁcantly (po0.01) increased
by BER induced HepG2 cells in a dose-dependent manner, but
there was no inﬂuence on the metabolism of chlorzoxazone,
metabolic activity of CYP1A2 and 3A4 could be signiﬁcantly induce
by BER at dose of 50–500 ng mL1.
3.4. Metabolic enzyme expression induced by BER
3.4.1. Expression of CYP1A2 and 3A4 mRNA expression in HepG2
cells
The mRNA expression of CYP1A2 and 3A4 in the HepG2 cells
was signiﬁcantly (po0.01) increased by induce of BER
(1 μg mL1) on three sequential days (Fig. 5).
Fig. 3. UPLC–MS/MS chromatograms of berberine in vitro HepG2 cells. A. blank sample, B. berberine.
Table 1
Effects of BER at different concentrations on survival rate of HepG2 cells.
Concentration (ng mL1) BER Control group
10 50 100 200 500 1000 /
Absorbance A 2.67770.046 2.64070.171 2.69870.190 2.69570.241 2.66470.162 2.60970.205 2.70070.201
Survival rate% 99.15 97.77 99.93 99.81 98.67 96.63 100
The absorbance value at 570 nm (mean7SD, n¼6).
Fig. 4. Metabolic rate ratio (%) of four probe drugs in HepG2 cell culture.
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3.4.2. Protein expression of CYP1A2 and 3A4 in HepG2 cells
The expression levels of CYP1A2 and 3A4 enzyme in the HepG2
cells were signiﬁcantly (po0.05 for CYP1A2 and po0.01 for 3A4)
increased by induction of 1 μg mL1 BER on three sequential days
(Figs. 6 and 7).
3.5. Method validation and its application
For the method validation, the speciﬁcation was veriﬁed by the
HepG2 cells in culture medium and standard solution. There was
no interference with the determination of probe drugs and BER
(Figs. 2 and 3). The linearity for each probe drug was at range of
20–1000 ng mL1, and there was a good linearity between con-
centration and peak area weighted by 1/x (Table 2, linearity). The
precision was determined at 20, 200 and 1000 ng mL1 for probe
drugs at range of 85.0–110% with the RSDo4.94%. The stability
was investigated for four probe drugs within 24 h, and the result
shown that the recovery was at range of 85.0–110% with
RSDo10% for all compounds. The recovery of the four probe
drugs ranged from 93.1% to 106.9% with the RSDo10%. For BER,
the linearity was at the range of 0.5–200 ng mL1 with correla-
tion coefﬁcient R240.99. The precision (1, 20 and 200 ng mL1
for BER) was less than 3.89%. The stability of BER in medium was
stable with the RSD less than 4.27%. The average recovery of BER
was 106.9% with RSDo2.1%. The LOD and LOQ for BER were 0.058
and 0.19 ng mL1, respectively.
Result suggested that the analytical method meets the require-
ment of the bio-analysis (Guidance for Industry, 2001; Tang et al.,
2009) and it can be used for the determination of the four probe
drugs and BER. When it is used to evaluate the metabolic potency
induced BER, the metabolism of midazolam, phenacetin, tolbutamide
could be signiﬁcantly induced by BER (range of 50–1000 ng mL1)
shown in Table 3.
4. Discussion
HepG2 cell is the human liver cancer cell with different gene
expression proﬁles from normal primacy or immortalized human
liver cell due to CYP3A4 enzyme lower but drug resistance factor-
related gene higher than normal cells. Compared with the human
hepatocyte model, it is easier to obtain without the complication of
species difference for rapid screening. In addition, it is easy to control
and perform for this model, which could accurately evaluate the
potential induce effect for drugs (Gebhardt et al., 2003; Lahoz et al.,
2013; Seeland et al., 2013; Westerink and Schoonen, 2007; Yoshitomi
et al., 2001;). CYP P450 enzyme is one of the most important enzyme
for drug metabolism, more than 75% of drug metabolism is mainly
mediated by CYP1A2, 3A4, 2C, 2D6, 2E1 and 2B6 enzymes (Cornish-
Bowden et al., 2004). Probe drugs for enzyme activity evaluation are
provided. Speciﬁcally, phenacetin, midazolam, chlorazol, and tolbu-
tamide are used for CYP1A2, CYP3A4, CYP2E1, and CYP2C9, respec-
tively (Blakey et al., 2004; Drug Development and Drug Interactions,
2011; Yuan et al., 2002). UPLC–MS/MS method was an useful tool for
substrates in HepG2 cells in vitro culture experiments (Tang et al.,
2009). The metabolic activity of substrates was assessed based on
clearance of which was inferior to analysis of metabolites generated
Fig. 5. CYP3A4 and CYP1A2 mRNA expression in HepG2 cells cultured with
berberine using RT–PCR. The “**” means po0.01 compared with the control group.
Fig. 6. Grayscale plot of protein expression of CYP1A2 and 3A4 in HepG2 cells
cultured with BER by western blotting. C-1, C-2 and C-3 are from the control group;
S-1, S-2 and S-3 are from the BER induced group.
Fig. 7. Relative protein expression ratio of CYP3A4 and CYP1A2 in HepG2 cells
cultured with berberine using western blotting. The “nn” means po0.01 and “n”
means po0.05 compared with the control group.
Table 2
Method validation of probe drugs and berberine.
Drugs Calibration Precision(%) Stability(%) Recovery(%)
Curve R2 Average RSD Average RSD Average RSD
Midazolam y¼0.0048Xþ0.0453 0.993 96.39 1.99 92.99 3.68 97.57 3.25
Phenacetin y¼0.0024X0.0035 0.997 89.12 2.36 96.26 3.68 97.24 1.09
Tolbutamide y¼0.0006X0.0034 0.998 88.65 4.13 88.83 8.91 93.13 1.51
Chlorzoxazone y¼0.0002Xþ0.0013 0.996 93.63 4.58 100.62 6.5 98.89 2.05
Berberine y¼0.0378Xþ0.0397 0.998 102.19 1.68 99.18 4.27 106.89 2.04
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in the speciﬁcity and accuracy tests (Timmerman et al., 2010). The
induction mechanism mainly involved the mRNA expression to
increase the metabolic activity (Harris et al., 2004; Ortiz de
Montellano et al., 2005; Gomez-Lechon et al., 2004; Guo et al.,
2011a, 2011b; Yoshitomi et al., 2001).
Via HepG2 cell model we found that BER could signiﬁcantly
increase the metabolism of midazolam, phenacetin and tolbuta-
mide with dose-dependence but no inﬂuence on metabolism of
chlorzoxazone, the inducers of rifampicin and omeprazole could
increase metabolic activity of CYP1A2 and 3A4 as well as inducer
of BER. The mRNA expression of CYP1A2 and 3A4 could be induced
signiﬁcantly by BER, CYP3A4 inducers may be also induce CYP2B6
and 2C (Blakey et al., 2004; Hutzler et al., 2002), which was
conﬁrmed by our results that BER increases the activity of CYP2C9.
Induce of CYP Enzyme and the activity of the transporter is one of
the common cases of metabolic enzymes or transporters associated
DDI (Bandyopadhyay et al., 2013; Gurley et al., 2008; Keith et al.,
2005; Lin et al., 1999; Nowack, 2008), although drug metabolism
inhibition more commonly results in DDIs, drug induce potency on
metabolism enzyme still causes serious consequences clinically (Teh
and Bertilsson, 2012). In conclusion, BER has the potential to induce
CYP1A2 and 3A4 enzymes, which may lead to treatment failure such
as midazolam, phenacetin and tolbutamide.
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